Dr. Reddy's Launches Cancer Medication in the UK

20 Mar 2024 , 11:42 AM

Versavo (bevacizumab) has been introduced by Dr. Reddy’s Laboratories to the UK market, the company announced in an exchange filing. This is Dr. Reddy’s first biosimilar product to be licensed and introduced to the UK market.

Metastatic colorectal cancer, advanced non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, advanced cervical cancer, ovarian cancer, and metastatic breast cancer are among the cancer types for which Versavo is authorized for treatment.

Versavo was first introduced by Dr. Reddy’s in India in 2019 as well as other nations like Thailand, Ukraine, Nepal, and Jamaica. In Colombia, the product was introduced under the Persivia brand.

Dr. Reddy’s worldwide Head of Biologics Jayanth Sridhar stated, “The launch of Versavo in a highly regulated market underscores our capability for global clinical development of high-quality biosimilar products.”

“This launch reinforces our commitment to bring more biosimilar and other critical biological products to meet the unmet needs of patients, and strengthens our focus on oncology,” he stated.

Versavo is a biosimilar to bevacizumab, the first antiangiogenic medication shown to impede the progression of metastatic cancer patients’ condition.
A complaint about gRevlimid was filed in a New Jersey district court on March 1st, and Dr. Reddy’s was listed as a defendant.

Walgreen Co., Kroger Specialty Pharmacy Inc., and CVS Pharmacy Inc. filed the complaint, citing federal antitrust laws as support for their claims.

Dr. Reddy’s, in association with Celgene Corporation, Bristol-Myers Squibb Co., Natco Pharma Ltd., and Teva Pharmaceuticals USA, Inc., has been accused by these companies of engaging in improper competition restraint and maintaining a shared monopoly in the sale of both brand and generic Revlimid through settlements of patent litigations.

At ₹6,201.60, shares of Dr. Reddy’s Laboratories are presently 2.2% down. Over the past 12 months, the stock has increased by around 40%.

For feedback and suggestions, write to us at [e-mail]